August 08, 2013 – Sandoz is excited to announce the re-launch of our biosimilars website, Sandoz-Biosimilars.com Sandoz is excited to announce the re-launch of our biosimilars website, Sandoz-Biosimilars.com . The site is a comprehensive educational resource, designed for visitors with varying levels of knowledge, that explains what biosimilars are, their importance, and how they are developed […]
SEATTLE, Aug. 7, 2013 /PRNewswire/ — Thousands of independent pharmacists will converge in Seattle for Cardinal Health’s annual Retail Business Conference August 7-10. This year’s event encourages independent pharmacies to Discover New Horizons for improving their businesses and for delivering quality, personalized care to patients. The tradeshow features a 95,000-square-foot trade exhibit floor, highlighting buying […]
Dublin, Ohio, July 26, 2013 — Cardinal Health executives will highlight forward-thinking supply chain solutions for the evolving healthcare landscape at the Association for Healthcare Resource and Materials Management (AHRMM) annual conference in San Diego July 28 – 31. Steve Inacker, president, Hospital Sales and Services at Cardinal Health will co-present at one of the conference’s […]
Holzkirchen, Germany, July 22, 2013 – Sandoz, the global leader in biosimilars, is pleased that Zarzio® (filgrastim) has become the first biosimilar to overtake both its reference product (Amgen’s Neupogen®) and European market leader (Chugai’s Granocyte®) and is now the most prescribed daily G-CSF in Europe and the #1 biosimilar daily G-CSF globally. The success of Zarzio […]
Princeton, New Jersey , July 02, 2013 – Sandoz today announced the US launch of metronidazole 1% topical gel, the first generic version of METROGEL® 1%. Metronidazole 1% topical gel is indicated for the topical treatment of inflammatory lesions of rosacea1, a condition that affects an estimated 16 million Americans.2 “This significant launch further expands our […]
– Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer’s; 24-week study showed statistically significant improvement in overall cognition and function compared to 4.6 mg/24h dose – Exelon Patch first and only transdermal therapy approved to treat all stages of Alzheimer’s – More than five million Americans are living with […]
New Tulsa Cancer Institute Offers Accuray’s Latest Cancer Fighting Technology SUNNYVALE, Calif., June 25, 2013 – Accuray Incorporated (Nasdaq: ARAY), announced today that the Tulsa Cancer Institute is the first U.S. center to treat a patient with Accuray’s TomoHDA™ System, the latest and most advanced innovation in the TomoTherapy® product lineage designed to treat the full spectrum of cancer […]
Holzkirchen, Germany, June 24, 2013 – Sandoz, the global leader in biosimilars, announced it has initiated a major Phase III clinical trial with its biosimilar version of etanercept (Amgen’s Enbrel®). Trial expected to support registration in the U.S. and European Union Sandoz continues to advance biosimilar pipeline with seven Phase III trials across five molecules Global […]
Tokyo, Japan, June 21, 2013 – Sandoz today announces the National Health Insurance price listing and launch in Japan of sodium risedronate tablets 2.5mg/17.5 mg [Sandoz], the generic version of BENET® Tablets / ACTONEL® Tab. Sodium risedronate tablets 2.5mg/17.5 mg are indicated for the treatment of osteoporosis. “Sandoz is proud to launch this important generic medicine, […]
June 19, 2013 – Sandoz is pleased that the European Medicines Agency (EMA) has issued a draft revised guideline on non-clinical and clinical issues in biosimilar product development. Overall, the draft revised guideline demonstrates EMA’s continued worldwide leadership in biosimilar regulations by applying science in a risk-based manner that safeguards patient safety without compromising access to […]